Welcome
Support Centre
21 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Randomised comparison of anticoagulation control and monitoring with versus without laboratory-provided computerized decision support
ISRCTN ISRCTN27244875
ClinicalTrials.gov identifier
Public title Randomised comparison of anticoagulation control and monitoring with versus without laboratory-provided computerized decision support
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis Laboratory-provided computerized decision support will improve anticoagulation control relative to usual care
Lay summary
Ethics approval Yes, August 2001
Study design Cluster-randomised controlled trial
Countries of recruitment Canada
Disease/condition/study domain Various
Participants - inclusion criteria Physicians:
1. Family or general practitioner
2. Full-time office practice
3. Practice address within study laboratory catchment area
4. At least 3 eligible patients willing to participate

Patients:
1. On long-term warfarin therapy
2. Using the study laboratory for international normalized ratio (INR) tests and expecting to continue to do so for at least 12 months
Participants - exclusion criteria None
Anticipated start date 01/01/2002
Anticipated end date 30/06/2003
Status of trial Completed
Patient information material
Target number of participants Physicians: 40; Patients: 380
Interventions Anticoagulation control and monitoring with versus without laboratory-provided computerized decision support (CDS)
Primary outcome measure(s) 1. Acceptability of the CDS service, as assessed by the proportion of physicians who would continue to use it if offered
2. Estimated effectiveness, as assessed by percentage of time within target INR range
Secondary outcome measure(s) Hemorrhagic and thromboembolic events requiring hospital attendance
Sources of funding Ontario Program for Optimal Therapeutics (Canada)
Trial website
Publications
Contact name Mr  Michael  Paterson
  Address ICES
G106-2075 Bayview Ave.
  City/town Toronto, Ontario
  Zip/Postcode M4N 3M5
  Country Canada
Sponsor Ontario Program for Optimal Therapeutics (Canada)
  Address 105 Main Street E, Level One
  City/town Hamilton, Ontario
  Zip/Postcode L8N 1G6
  Country Canada
Date applied 08/11/2005
Last edited 14/09/2009
Date ISRCTN assigned 25/11/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central